Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Coronavirus Pep02,AddaVax
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Longhorn Vaccines and Diagnostics to Present at Infectious Disease Week 2022
Details : Coronavirus Pep02 Composite Peptide Vaccines comprised of Coronavirus (SARS-CoV-2 RNA Polymerase) and Influenza epitopes (Tetanus T cell epitope) Generated Antisera Reponses to Both Coronavirus and Influenza.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
October 19, 2022
Lead Product(s) : Coronavirus Pep02,AddaVax
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?